^
    Back
    Association details:
    Biomarker:SMARCA4 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Immunol
    Title:

    Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab

    Published date:
    03/27/2023
    Excerpt:
    Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab.
    DOI:
    https://doi.org/10.3389/fimmu.2023.1131448